New Partnership to Accelerate the Fight Against Alzheimer’s Disease
World Economic Forum will partner over the next year with the Global CEO Initiative (CEOi) to form a Coalition to accelerate treatments for Alzheimer’s Disease
UsAgainstAlzheimer’s Launches Online Biomarkers Repository to Track Alzheimer’s Research
In an important step to advance Alzheimer’s research, UsAgainstAlzheimer’s today announced the creation of a new online Biomarkers Repository to track research into Alzheimer’s biomarkers and diagnostics. The constantly-evolving Biomarkers Repository will help policymakers, healthcare system leaders and scientific community better understand and support personalized medicine.
The prescription for an effective treatment or cure for Alzheimer’s: More research and cautious optimism
It’s been an exciting few weeks in the Alzheimer’s world – a world that hasn’t seen a new drug in 15 years. All of the activity has raised a lot of questions around the world’s progress toward a cure.
It’s time to pick up the pace on Alzheimer’s prevention
Milken Institute report urges our nation to double down on efforts to reduce the cost and risk of dementia and outlines a series of recommended action steps.
Four Leading Alzheimer’s Organizations Agree on Need For National, Time-Based Prevention Goal
Director of the National Center for Chronic Disease Prevention and Health Promotion, Senior Director of Center for the Future of Aging, and Leading U.S. Alzheimer’s Researcher Resoundingly Support UsAgainstAlzheimer’s Call for a Time-based Alzheimer’s Prevention Goal
UsAgainstAlzheimer’s Applauds Positive News on Alzheimer’s Drug Aducanumab
Statement from George Vradenburg on the announcement by Biogen and Eisai of plans to seek regulatory approval in early 2020 by the Food and Drug Administration (FDA) for aducanumab, an investigational treatment for early Alzheimer’s disease.